Biointerventional solutions for heart failure, chronic myocardial ischemia, and acute myocardial infarction


November 18, 2016
BioCardia Chairman of the Board Letter to Shareholders

October 24, 2016
BioCardia Closes Merger with Tiger X Medical, Inc.

August 22, 2016
BioCardia, Inc. Signs Merger Agreement with Tiger X Medical, Inc., Secures Funding to Support Further Development of CardiAMP® Cell Therapy System for the Treatment of Heart Failure

May 23, 2016
BioCardia® receives award from the Maryland Stem Cell Research Fund for CardiAMP cell therapy program for the treatment of ischemic heart failure

May 9, 2016
BioCardia® Receives US Patent Covering a Method of Producing Mesenchymal Stem Cells Using a Single Patient Donor for Both Source Cells and Culture Medium

Feb 21, 2016
BioCardia®, Inc. Announces Two Presentations Related to Cardiamp Cell Therapy at Cardiovascular Research Technologies in Washington, DC

Jan 28, 2016
BioCardia Announces Upcoming Cell Therapy Presentations at Cardiovascular Research Technologies Conference

more news



We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. 

These programs are enabled by the Company's Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.